SOT Sothema
Sothema (SOT) news
Sothema is a public biotech or pharmaceutical company listed on CSEMA under the ticker SOT, recorded under Morocco. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Sothema news
We have not published a story on Sothema yet. When there is news, it will appear here.
Questions about Sothema
What is the ticker symbol of Sothema?
Sothema trades under the ticker SOT on CSEMA.
Where is Sothema listed?
Sothema is listed on CSEMA.
Which country or territory is Sothema listed under?
Our directory records Sothema under Morocco.
What does Sothema do?
Our directory classifies Sothema as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Sothema?
The ISIN recorded for Sothema is MA0000012833.
Does aibio.space cover Sothema?
aibio.space lists Sothema among 2,820 public biotech companies and publishes its news here as stories appear.
Investor discussion: Sothema
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Listing details
- Company
- Sothema
- Ticker
- SOT
- Listing
- CSEMA
- Country or territory
- Morocco
- Business scope
- Pharmaceuticals: Major
- ISIN
- MA0000012833
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio